Citadel Advisors
IMCR icon

Citadel Advisors’s Immunocore IMCR Stock Holding History

Citadel Advisors’s Portfolio IMCR Stock Details IMCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18M Buy
566,761
+336,362
+146% +$9.95M ﹤0.01% 2728
2026
Q1 		$6.95M Sell
230,399
-3,869
-2% -$125K ﹤0.01% 3821
2025
Q4 		$8.13M Buy
234,268
+192,070
+455% +$6.78M ﹤0.01% 3529
2025
Q3 		$1.53M Sell
42,198
-162,019
-79% -$5.5M ﹤0.01% 6618
2025
Q2 		$6.41M Buy
204,217
+150,581
+281% +$4.68M ﹤0.01% 3702
2025
Q1 		$1.59M Sell
53,636
-22,034
-29% -$661K ﹤0.01% 5976
2024
Q4 		$2.23M Buy
75,670
+16,562
+28% +$524K ﹤0.01% 5400
2024
Q3 		$1.84M Sell
59,108
-169,844
-74% -$6.18M ﹤0.01% 5695
2024
Q2 		$7.76M Buy
228,952
+166,927
+269% +$8.51M ﹤0.01% 3121
2024
Q1 		$4.03M Sell
62,025
-178,331
-74% -$12.2M ﹤0.01% 4287
2023
Q4 		$16.4M Buy
240,356
+68,784
+40% +$3.58M ﹤0.01% 2231
2023
Q3 		$8.9M Buy
171,572
+135,695
+378% +$8.03M ﹤0.01% 2837
2023
Q2 		$2.15M Sell
35,877
-24,445
-41% -$1.4M ﹤0.01% 5028
2023
Q1 		$2.98M Sell
60,322
-139,266
-70% -$7.83M ﹤0.01% 4643
2022
Q4 		$11.4M Sell
199,588
-94,814
-32% -$5.34M ﹤0.01% 2645
2022
Q3 		$13.8M Buy
294,402
+209,902
+248% +$10M ﹤0.01% 2328
2022
Q2 		$3.15M Buy
84,500
+24,774
+41% +$805K ﹤0.01% 4670
2022
Q1 		$1.79M Buy
59,726
+47,603
+393% +$1.2M ﹤0.01% 6336
2021
Q4 		$415K Sell
12,123
-10,405
-46% -$377K ﹤0.01% 10117
2021
Q3 		$835K Sell
22,528
-28,782
-56% -$971K ﹤0.01% 8589
2021
Q2 		$2M Sell
51,310
-126
-0.2% -$4.86K ﹤0.01% 6616
2021
Q1 		$2.19M Buy
+51,436
New +$2.29M ﹤0.01% 6181

Other funds holding IMCR

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors's IMCR Position: Q2 2026 in Review

Citadel Advisors increased its Immunocore (IMCR) stake by 146% in Q2 2026, buying an estimated $9.95M and bringing the position to 566,761 shares worth $18M. The position accounts for ﹤0.01% of the portfolio, ranked #2728.

Citadel Advisors first reported a position in IMCR in Q1 2021 and has held it in 22 quarters since. 136 funds tracked by Wall St. Rank hold IMCR as of Q2 2026.

  • Citadel Advisors held 566,761 shares of Immunocore worth $18M as of Q2 2026.
  • Citadel Advisors bought 336,362 Immunocore shares in Q2 2026, an estimated $9.95M.
  • Immunocore made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #2728 holding.
  • Citadel Advisors first reported a position in Immunocore in Q1 2021 and has held it in 22 quarters since.
  • 136 funds tracked by Wall St. Rank held Immunocore as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.